Provides gene synthesis and molecular cloning services. Offers oligonucleotide synthesis services. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 17% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 20% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 17% a year on average.
The company sells $960.9M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $533.6M against $960.9M in annual sales.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.